What is the use of vildagliptin and metformin HCL tablets?
About vildagliptin
| Type of medicine | An antidiabetic medicine |
|---|---|
| Used for | Adults with type 2 diabetes mellitus |
| Also called | Galvus®; Eucreas® (a combination tablet containing vildagliptin with metformin) |
| Available as | Tablets |
What is Galvus Met 50 850 used for?
Galvus Met 50 mg/850 mg Tablet 15’s is a combination drug of Vildagliptin (DPP-4 inhibitor), and Metformin (Biguanides) belongs to the class of anti-diabetic. Type 2 diabetes mellitus used to be known as ‘non-insulin-dependent diabetes mellitus (NIDDM)’ or ‘maturity-onset diabetes’.
What are the benefits of vildagliptin?
What is the use of vildagliptin? The medication is used for the treatment of Type 2 diabetes mellitus. This is used along with diet and exercise to improve blood sugar control in adults with Type 2 diabetes. The medication is a type of anti-diabetic drug.
What is the side effect of vildagliptin?
Nasopharyngitis, headache and dizziness are the most common adverse effects associated with vildagliptin, occurring in 6 – 9% of patients.
Is vildagliptin safe for kidneys?
Vildagliptin can be safely used in T2DM patients with varying degrees of renal impairment. Dose adjustments for renal impairment are required. Potential long-term renal benefit of vildagliptin needs to be further explored.
Which is better vildagliptin and metformin?
Conclusions: Vildagliptin is an effective and well-tolerated treatment option in elderly patients with type 2 diabetes, demonstrating similar improvement in glycaemic control as metformin, with superior GI tolerability.
How does vildagliptin work in the body?
The active substance in Galvus, vildagliptin, is a dipeptidyl peptidase 4 (DPP-4) inhibitor. It works by blocking the breakdown of incretin hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin.
Is vildagliptin safe for long term?
Conclusion. In conclusion, vildagliptin as add-on to insulin treatment for 24 months was well tolerated and led to sustained reductions in HbA1c, the dose and frequency of insulin injections, and the risk of hypoglycemia in patients with T2DM.
